Aldafermin a hit in nonalcoholic steatohepatitis
Use of aldafermin, an engineered analogue of FGF19, appears beneficial in the treatment of patients with nonalcoholic steatohepatitis (NASH), reducing liver fat and markers of disease progression without any adverse side effects, according to the results of a phase II trial.
